5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions
| العنوان: | 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions |
|---|---|
| المؤلفون: | Christian W. Hamm, Jean Fajadet, Yoshinobu Onuma, Pascal Vranckx, Tessa Rademaker, Carlos Macaya, Monique Schuijer, Kristel Wittebols, Arts Ii Investigators, Scot Garg, Marie-Claude Morice, Patrick W. Serruys, Bernard De Bruyne, Antonio Colombo, Gert Richardt, Hans Peter Stoll |
| المساهمون: | Cardiology, Hematology |
| المصدر: | Journal of the American College of Cardiology, 55(11), 1093-1101. Elsevier Inc. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Coronary Artery Disease, Revascularization, multivessel disease, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Humans, Myocardial infarction, cardiovascular diseases, Angioplasty, Balloon, Coronary, Coronary Artery Bypass, Survival rate, Antibacterial agent, Aged, Sirolimus, business.industry, Stent, Drug-Eluting Stents, Middle Aged, medicine.disease, Surgery, surgical procedures, operative, Treatment Outcome, Drug-eluting stent, Cardiology, sirolimus-eluting stent, Female, business, Cardiology and Cardiovascular Medicine, Mace, long-term outcomes |
| الوصف: | Objectives The purpose of this study is to compare the 5-year clinical outcomes, safety, and efficacy of sirolimus-eluting stents (SES) in the ARTS II (Arterial Revascularization Therapies Study II) with the outcomes of coronary artery bypass graft (CABG) and bare-metal stenting (BMS) from the ARTS I. Background The long-term outcomes after SES implantation in patients with multivessel disease remains to be established. Methods The ARTS I was a randomized trial of 1,205 patients with multivessel disease comparing CABG and BMS. The ARTS II study was a nonrandomized trial with the Cypher sirolimus-eluting stent (Cordis, a Johnson & Johnson Company, Warren, New Jersey), applying the same inclusion and exclusion criteria, end points, and protocol definitions. The ARTS II trial enrolled 607 patients, with an attempt to enroll at least one-third of patients with 3-vessel disease. Results At 5-year, the death/stroke/myocardial infarction event-free survival rate was 87.1% in ARTS II SES, versus 86.0% (p = 0.1) and 81.9% (p = 0.007) in ARTS I CABG and BMS cohorts, respectively. The 5-year major adverse cardiac and cerebrovascular event (MACCE) rate in ARTS II (27.5%) was significantly higher than ARTS I CABG (21.1%, p = 0.02), and lower than in ARTS I BMS (41.5%, p = 0.001). The cumulative incidence of definite stent thrombosis was 3.8%. Thirty-two percent (56 of 176) of major adverse cardiac events (MACE) at 5 years were related to possible, probable, or definite stent thrombosis. Conclusions At 5 years, SES had a safety record comparable to CABG and superior to BMS, and a MACCE rate that was higher than in patients treated with CABG, and lower than in those treated with BMS. Approximately one-third of the events seen with SES could be prevented through the elimination of early, late, and very late stent thrombosis. (J Am Coll Cardiol 2010;55:1093-101) (C) 2010 by the American College of Cardiology Foundation |
| تدمد: | 1558-3597 0735-1097 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3100f9e4bab151d15f7c8d0370864aa6 https://pubmed.ncbi.nlm.nih.gov/20171036 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3100f9e4bab151d15f7c8d0370864aa6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15583597 07351097 |
|---|